PE20090141A1 - Compuestos derivados de isoquinolina proceso de preparacion y composicion farmaceutica - Google Patents

Compuestos derivados de isoquinolina proceso de preparacion y composicion farmaceutica

Info

Publication number
PE20090141A1
PE20090141A1 PE2008000613A PE2008000613A PE20090141A1 PE 20090141 A1 PE20090141 A1 PE 20090141A1 PE 2008000613 A PE2008000613 A PE 2008000613A PE 2008000613 A PE2008000613 A PE 2008000613A PE 20090141 A1 PE20090141 A1 PE 20090141A1
Authority
PE
Peru
Prior art keywords
alkyl
alcoxy
halo
compounds derived
pharmaceutical composition
Prior art date
Application number
PE2008000613A
Other languages
English (en)
Inventor
Matthew Hallam
Barrie Martin
Piotr Raubo
Bryan Roberts
Stephen St-Gallay
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090141A1 publication Critical patent/PE20090141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ISOQUINOLINA DE FORMULA I, DONDE R1 ES H, ALQUILO(C1-C6), ALQUENILO(C3-C6), (CR101R102)a-X-Ar, ENTRE OTROS; R101 ES ALQUILO(C1-C6); R102 ES H O ALQUILO(C1-C6); R2 Y R3 SON H, HALO, ALQUILO(C1-C6), ALCOXI(C1-C6) Y (CH2)d-Y; R4 Y R5 SON H, ALQUILO(C1-C6), ALCOXI(C1-C6), HALO, CF3 Y CN; R6 ES ARILO, OH, CICLOALQUILO(C3-C7), ENTRE OTROS; R7 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6) Y HALO; Ar ES ANILLO ARILO O HETEROARILO; X ES UN ENLACE SIMPLE O NR14 Y S(O)g; Y ES HETEROCICLOALQUILO, O-(CH2)h-NR16R17, NR18-(CH2)h-NR16R17, ENTRE OTROS; a ES DE 0 A 6; d Y h SON DE 0 A 3; g ES DE 0 A 2; R14, R16, R17 Y R18 SON H O ALQUILO(C1-C6). SON PREFERIDOS: 3-(2-BENCIL-1-OXO-1,2-DIHIDRO-ISOQUINOLIN-6-IL)-N-CICLOPROPIL-4-METILBENZAMIDA, 3-(4-(((2R,4S)-4-AMINO-2-(HIDROXIMETIL)PIRROLIDIN-1-IL)METIL)-2-(CICLOPROPILMETIL)-1-OXO-1,2-DIHIDRO-ISOQUINOLIN-6-IL)-N-CICLOPROPIL-5-FLUORO-4-METILBENZAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA P38 QUINASA UTILEN EN EL TRATAMIENTO DE ASMA, ARTRITIS, PSORIASIS, ENFERMEDAD OBSTRUCTIVA CRONICA, ENTRE OTRAS
PE2008000613A 2007-04-05 2008-04-04 Compuestos derivados de isoquinolina proceso de preparacion y composicion farmaceutica PE20090141A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91023507P 2007-04-05 2007-04-05
US97952307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
PE20090141A1 true PE20090141A1 (es) 2009-04-30

Family

ID=39560895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000613A PE20090141A1 (es) 2007-04-05 2008-04-04 Compuestos derivados de isoquinolina proceso de preparacion y composicion farmaceutica

Country Status (19)

Country Link
US (1) US8012979B2 (es)
EP (1) EP2144881B1 (es)
JP (1) JP5400759B2 (es)
KR (1) KR20100016218A (es)
CN (1) CN101679275B (es)
AR (1) AR065965A1 (es)
AU (1) AU2008235359B2 (es)
BR (1) BRPI0810047A2 (es)
CA (1) CA2681221A1 (es)
CL (1) CL2008000973A1 (es)
CO (1) CO6230983A2 (es)
EC (1) ECSP099679A (es)
IL (1) IL201015A0 (es)
MX (1) MX2009010225A (es)
PE (1) PE20090141A1 (es)
RU (1) RU2472781C2 (es)
TW (1) TW200845988A (es)
UY (1) UY31005A1 (es)
WO (1) WO2008122765A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073711A1 (es) * 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN103864684A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109251211B (zh) * 2016-12-21 2025-03-07 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一类喹诺酮羧酸化合物及其中间体、制备方法以及应用
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU176214B (en) * 1977-05-18 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 5,6-dihydro-imidazo-square bracket-5,1-a-square bracket closed-isoquinolin derivatives
DE60010448T2 (de) 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
US7402595B2 (en) * 2002-02-13 2008-07-22 Takeda Pharmaceutical Company Limited JNK inhibitor
US6867320B2 (en) 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
AU2003211384B2 (en) * 2002-02-21 2008-12-11 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
KR101175371B1 (ko) 2003-08-06 2012-08-20 바스프 에스이 하나 이상의 유기 화합물의 연속 불균일 촉매적 기체상부분 산화 수행 방법
KR20060079190A (ko) * 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
UY29301A1 (es) * 2004-12-24 2006-07-31 Astrazeneca Ab Derivados amida
TW200728277A (en) * 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
HRP20110839T1 (hr) 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze

Also Published As

Publication number Publication date
JP5400759B2 (ja) 2014-01-29
EP2144881A1 (en) 2010-01-20
AR065965A1 (es) 2009-07-15
US20090023746A1 (en) 2009-01-22
IL201015A0 (en) 2010-05-17
UY31005A1 (es) 2008-11-28
RU2472781C2 (ru) 2013-01-20
ECSP099679A (es) 2009-11-30
KR20100016218A (ko) 2010-02-12
CL2008000973A1 (es) 2009-01-02
CN101679275B (zh) 2013-07-31
EP2144881B1 (en) 2012-06-20
US8012979B2 (en) 2011-09-06
CA2681221A1 (en) 2008-10-16
MX2009010225A (es) 2009-12-14
TW200845988A (en) 2008-12-01
RU2009136246A (ru) 2011-05-10
AU2008235359B2 (en) 2011-12-15
CO6230983A2 (es) 2010-12-20
CN101679275A (zh) 2010-03-24
BRPI0810047A2 (pt) 2014-10-21
WO2008122765A1 (en) 2008-10-16
AU2008235359A1 (en) 2008-10-16
JP2010523533A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
EA200601266A1 (ru) Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
TW200635585A (en) Monocyclic substituted methanones
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
DK1814846T3 (da) 11beta-HSD1-inhibitorer
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
SE0403171D0 (sv) New compounds
ATE466860T1 (de) Cgrp-rezeptorantagonisten
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MX2010003942A (es) Nuevos inhibidores de epoxido hidrolasa soluble y su uso.
SE0400043D0 (sv) New compounds
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
SE0400970D0 (sv) Nicotinic acetylcholine receptor ligands
ATE503755T1 (de) Cgrp-rezeptorantagonisten
PE20140998A1 (es) Compuestos heterociclicos como inhibidores de syk

Legal Events

Date Code Title Description
FD Application declared void or lapsed